Daunorubicin HCl

製品コードS3035 バッチS303503

化学情報

	Synonyms	Rubidomycin HCl, RP 13057 HCl	Storage (From the date of receipt)	3 years -20°C powder 1 years -80°C in solvent
	化学式	C₂₇H₂₉NO₁₀ . HCl
	分子量	563.98	CAS No.	23541-50-6
Solubility (25°C)*	体外	DMSO	100 mg/mL (177.31 mM)
		Water	100 mg/mL (177.31 mM)
		Ethanol	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with K_i of 0.02 μM in a cell-free assay. Daunorubicin is a topoisomerase II inhibitor that induces apoptosis.
in vitro	At drug concentrations that reflect the peak plasma concentration after Daunorubicin administration, the primary mechanism is likely to be through interaction with topoisomerase II, which may be a primary triggering event for growth arrest and/or cell killing through a signalling pathway leading to apoptosis, at least in leukemic cells and thymocytes. The quinone structure permits daunorubicin to act as electron acceptors in reactions mediated by oxoreductive enzymes including cytochrome P450 reductase, NADH dehydrogenase, and xanthine oxidase. At Daunorubicin concentrations exceeding approximately 2–4 μM, free radical mediated toxicity and DNA cross-linking may become evident. Daunorubicin inhibits both DNA and RNA syntheses in HeLa cells over a concentration range of 0.2 through 2 μM. Daunorubicin inhibits both DNA syntheses in Ehrlich ascites tumor cells over a concentration range of 4 μM. Daunorubic triggers apoptosis at concentrations of 0.5 and 1 μM in either HL-60 or U-937 human leukemic cells. ^[1] Daunorubicin stimulates ceramide elevation and apoptosis in P388 and U937 cells through de novo synthesis via activation of the enzyme ceramide synthase. ^[2] Daunorubicin dose-dependently increases the phosphatidylserine exposure and consequent procoagulant activity of human umbilical vein endothelial cells. Daunorubicin (0.2 mM) significantly enhances the release of endothelial microparticles which are highly procoagulant in human umbilical vein endothelial cells. ^[3]

製品説明

Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with K_i of 0.02 μM in a cell-free assay. Daunorubicin is a topoisomerase II inhibitor that induces apoptosis.

in vitro

At drug concentrations that reflect the peak plasma concentration after Daunorubicin administration, the primary mechanism is likely to be through interaction with topoisomerase II, which may be a primary triggering event for growth arrest and/or cell killing through a signalling pathway leading to apoptosis, at least in leukemic cells and thymocytes. The quinone structure permits daunorubicin to act as electron acceptors in reactions mediated by oxoreductive enzymes including cytochrome P450 reductase, NADH dehydrogenase, and xanthine oxidase. At Daunorubicin concentrations exceeding approximately 2–4 μM, free radical mediated toxicity and DNA cross-linking may become evident. Daunorubicin inhibits both DNA and RNA syntheses in HeLa cells over a concentration range of 0.2 through 2 μM. Daunorubicin inhibits both DNA syntheses in Ehrlich ascites tumor cells over a concentration range of 4 μM. Daunorubic triggers apoptosis at concentrations of 0.5 and 1 μM in either HL-60 or U-937 human leukemic cells. ^[1]

Daunorubicin stimulates ceramide elevation and apoptosis in P388 and U937 cells through de novo synthesis via activation of the enzyme ceramide synthase. ^[2]

Daunorubicin dose-dependently increases the phosphatidylserine exposure and consequent procoagulant activity of human umbilical vein endothelial cells. Daunorubicin (0.2 mM) significantly enhances the release of endothelial microparticles which are highly procoagulant in human umbilical vein endothelial cells. ^[3]

プロトコル(参考用のみ)

細胞アッセイ	細胞株	THTC-07 cells
	濃度	10 µM
	反応時間	24 h
	実験の流れ	Cells were treated with various concentrations of drug.
動物実験	動物モデル	Male Sprague–Dawley rats
	投薬量	3 mg/kg
	投与方法	i.v.

参考

+ 展开

カスタマーフィードバック

: , , Leuk Res, 2015, 39(4):435-44.

: Data from [Data independently produced by , , J Transl Med, 2016, 14(1):132]

: Data from [Data independently produced by , , Mol Cell Biochem, 2017, 434(1-2):25-32]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation [ Cell Stem Cell, 2023, 10.1016/j.stem.2023.09.011]	PubMed: 37863054
Transcriptional Response to Standard AML Drugs Identifies Synergistic Combinations [ Int J Mol Sci, 2023, 24(16)12926]	PubMed: 37629110
Bone Marrow Microenvironment-Induced Chemoprotection in KMT2A Rearranged Pediatric AML Is Overcome by Azacitidine-Panobinostat Combination [ Cancers (Basel), 2023, 15(12)3112]	PubMed: 37370721
Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro [ Sci Rep, 2023, 13(1):21054]	PubMed: 38030645
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia [ Nat Cancer, 2022, 3(7):837-851]	PubMed: 35668193
Elucidating minimal residual disease of paediatric B-cell acute lymphoblastic leukaemia by single-cell analysis [ Nat Cell Biol, 2022, 10.1038/s41556-021-00814-7]	PubMed: 35145224
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in Acute Myeloid Leukemia [ Blood, 2022, blood.2022016090]	PubMed: 36219880
Generating experimentally unrelated target molecule-binding highly functionalized nucleic-acid polymers using machine learning [ Nat Commun, 2022, 13(1):4541]	PubMed: 35927274
Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells [ J Clin Invest, 2022, 132(16)e153514]	PubMed: 35763353
Population-based high-throughput toxicity screen of human iPSC-derived cardiomyocytes and neurons [ Cell Rep, 2022, 39(1):110643]	PubMed: 35385754

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。